Exosomics was born in 2011 as spin-off of HansaBioMed OU for the exploitation of technologies applied to the oncological diagnostics. Exosomics is located at Medical Research Center of Toscana Life Sciences Foundation since 2012 and represents a very innovative company in the oncology field. The main company interests are new platforms for cancer screening and diagnostics for personalized therapie of oncological patients. Exosomics employs the exsomomes properties as markers vehicles in the peripheral blood in order to obtain relevant diagnostic information. As Antonio Chiesi, company founder and CEO, explains in his interview, the exosomes are lipid nanoparticles released in the biological fluids from all cells and, in particular, from the cancer tissues, which transmit disease’s markers (proteins and nucleic acids) in the blood. Through the content analysis of these nanoparticles it is possible to obtain an accurate cancer diagnosis.
The aim of Exosomics Siena is to revolutionize the oncology diagnostics field through the use of screening essays for the precision medicine with an high innovation content.
The company asset has recently increased with the arrival of an important international partner, LONZA, which invested on technologies and on the innovative approach proposed by Exosomics to improve the cancer diagnostics. The company also cooperates with many national and international clinical groups in the development and validation of its own diagnostic products and in the optimisation of innovative technologies in the field of liquid biopsy.